Company Overview - American Resources Corporation (NASDAQ:AREC) announced a private placement deal, resulting in a 3.18% increase in after-hours trading to $5.17, despite a 26.43% decline to $5.01 during regular trading on the same day [1]. Private Placement Details - The company signed a securities purchase agreement to sell 7,843,138 shares of Class A common stock or pre-funded warrants at a price of $5.10 per share [2]. - The expected gross proceeds from this offering are approximately $40 million, before deducting placement agent fees and other costs, with the offering anticipated to close on October 16, pending usual closing conditions [3]. Regulatory Compliance - The securities are being sold under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, with the company agreeing to file a registration statement with the SEC for resale of the securities [4]. Sector Context - The private placement occurs amid heightened investor interest in rare earth stocks, with notable commentary from CNBC's Jim Cramer describing the sector as "on fire" due to ongoing concerns regarding critical mineral supply chains [5]. - JPMorgan Chase & Co. has also announced a $1.5 trillion initiative focused on critical minerals, further boosting sector momentum [5]. Stock Performance - Over the past year, AREC has experienced a significant gain of 391.18%, reaching a 12-month high of $6.81 [6]. - The stock has traded within a range of $0.38 to $7.11 over the past year and currently has a market capitalization of $423.89 million, with an average daily trading volume of 6.95 million shares [6]. Market Momentum - Benzinga's Edge Stock Rankings indicate that AREC is exhibiting a strong upward price trend, with momentum in the 98th percentile across all time frames [7].

Core Viewpoint - American Resources Corporation has entered into a securities purchase agreement for the sale of 7,843,138 shares of class A common stock at an offering price of $5.10 per share, aiming to raise approximately $40.0 million in gross proceeds before expenses [1]. Company Summary - The company is a leader in the critical mineral supply chain [1]. - The private placement involves institutional investors and includes the option for pre-funded warrants [1]. - The estimated gross proceeds from the offering are approximately $40.0 million, which will be used for corporate purposes [1].

FISHERS, IN / ACCESS Newswire / October 13, 2025 / American Resources Corporation (NASDAQ:AREC) ("American Resources" or the "Company"), a leader in the critical mineral supply chain, today announced that it has entered into a securities purchase agreement with several institutional investors for the purchase and sale of 9,480,282 shares of class A common stock at an offering price of $3.55 per share, in a private placement (the "Offering"). The gross proceeds to the Company from the Offering are estimated ...

Core Viewpoint - Mirion Technologies, Inc. announced the pricing of an underwritten public offering of 17,309,846 shares of its Class A common stock at a price of $21.35 per share, increasing the offering size from the previously announced $350 million [1] Group 1 - The public offering consists of 17,309,846 shares of Class A common stock [1] - The offering price is set at $21.35 per share [1] - The size of the offering was increased from the previously announced $350 million [1] Group 2 - Mirion granted underwriters an option to purchase up to an additional 2,596,476 shares [1]

Core Viewpoint - Immuneering Corporation has announced a proposed underwritten public offering of its Class A common stock and a concurrent private placement with Sanofi for $25 million, aimed at advancing its oncology product candidates and general corporate purposes [1][2]. Group 1: Offering Details - The public offering includes shares of Class A common stock and pre-funded warrants, with underwriters granted a 30-day option to purchase an additional 15% of the offered shares [1]. - Sanofi will purchase $25 million worth of Immuneering's Class A common stock or non-voting Class B common stock at the public offering price, in a private placement expected to close concurrently with the public offering [1][2]. - The offering is subject to market conditions and the private placement is contingent upon the closing of the public offering [1]. Group 2: Use of Proceeds - The net proceeds from both the public offering and private placement will be utilized to advance preclinical and clinical development of product candidates, as well as for working capital and other general corporate purposes [2]. Group 3: Regulatory Information - The offering is being conducted under a shelf registration statement filed with the SEC, which was declared effective on August 20, 2025 [3]. - A preliminary prospectus supplement will be filed with the SEC, and copies will be available through the underwriters [3][7]. Group 4: Securities Registration - The shares sold in the private placement will not be registered under the Securities Act of 1933 and cannot be offered or sold in the U.S. without registration or an applicable exemption [4].

Group 1 - BitGo Holdings, Inc. has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed underwritten initial public offering of its Class A common stock [1] - The specific timing of the offering, the number of shares to be offered, and the price range for the proposed offering have not yet been determined [1]

Core Viewpoint - Sidus Space, Inc. intends to offer shares of its Class A common stock and/or pre-funded warrants in a best-efforts public offering [1] Company Overview - Sidus Space, Inc. is described as an innovative and agile space and defense technology company [1] - The company provides flexible and cost-effective solutions to government, defense, intelligence, and commercial sectors globally [1]

Group 1 - Figure Technology Solutions, Inc. announced the pricing of its initial public offering (IPO) of 31,500,000 shares of Class A common stock at a public offering price of $25.00 per share [1] - The shares are expected to begin trading on the Nasdaq Global Select Market on September 11, 2025, under the ticker symbol "FIGR" [1] - The offering is anticipated to close on September 12, 2025, subject to the satisfaction of customary closing conditions [1]

Core Viewpoint - Evolent Health, Inc. plans to offer $140 million in convertible senior notes due 2031, with an option for initial purchasers to buy an additional $20 million, aimed at improving financial flexibility and supporting share repurchases [1][2]. Group 1: Offering Details - The offering consists of $140 million aggregate principal amount of convertible senior notes due 2031, subject to market conditions [1]. - Evolent expects to use up to $100 million of the net proceeds to repurchase a portion of its existing 1.50% convertible senior notes due 2025 and approximately $40 million for repurchasing shares of its Class A common stock [2]. - The notes will be convertible into cash, shares of Evolent's Class A common stock, or a combination thereof, with interest payable semiannually starting February 15, 2026 [4]. Group 2: Repurchase Strategy - Evolent plans to repurchase shares of its Class A common stock sold short by initial investors at a price equal to the last reported sale price on the pricing date, which may influence the market price of the stock [3]. - The company anticipates that holders of the 2025 Notes who agree to have their notes repurchased may unwind their hedges by buying Evolent's Class A common stock, potentially affecting the stock price [6]. Group 3: Conversion Rights - The conversion rights of the notes may be terminated by Evolent on or after August 20, 2026, under specific conditions related to the stock price performance [5]. - The conversion price and other terms of the notes will be determined at the time of the offering's pricing [4]. Group 4: Regulatory Information - The notes and any Class A common stock issued upon conversion will not be registered under the Securities Act, and may only be offered to qualified institutional buyers [7]. - The press release does not constitute an offer to sell or a solicitation to buy the securities described [8]. Group 5: Company Overview - Evolent Health specializes in improving health outcomes for individuals with complex conditions, serving a national base of leading payers and providers [9].

Core Viewpoint - Simmons First National Corporation has announced a public offering of 16,220,000 shares of its Class A common stock at a price of $18.50 per share, totaling approximately $300 million [1][2]. Group 1: Offering Details - The public offering is priced at $18.50 per share, with an aggregate offering amount of $300,070,000 [1]. - The company has granted underwriters a 30-day option to purchase an additional 2,433,000 shares at the public offering price [1]. - The offering is expected to close on or about July 23, 2025, subject to customary conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, which may include investments in Simmons Bank to support potential balance sheet repositioning and continued growth [2]. Group 3: Company Background - Simmons First National Corporation is a financial holding company based in the Mid-South, with a history of paying cash dividends for 116 consecutive years [6]. - Its principal subsidiary, Simmons Bank, operates over 220 branches across several states, including Arkansas, Kansas, Missouri, Oklahoma, Tennessee, and Texas [6]. - Simmons Bank has received multiple recognitions, including being named one of America's Best Regional Banks 2025 by Newsweek [6].